Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED)

Authors not listed

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · 2008

Abstract

Patients with Pigment Epithelial Detachments secondary to Age-Related Macular Degeneration (AMD) will receive intravitreal Lucentis monthly for 6 months in the hope of improving visual acuity from a baseline evaluation.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2008). Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED). <em>London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's</em>. https://clinicaltrials.gov/study/NCT00841581
Vancouver
Anonymous. Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED). London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. 2008.
BibTeX
@misc{anon2008Intrav, title = {Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED)}, author = {Anonymous}, journal = {London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's}, year = {2008}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings